10x Genomics, Inc. (NASDAQ:TXG) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET

Company Participants

Cassie Corneau – Head-Investor Relations & Strategic Finance

Serge Saxonov – Chief Executive Officer and Co-founder

Justin McAnear – Chief Financial Officer

Conference Call Participants

Dan Arias – Stifel

Dan Brennan – Cowen

Tejas Savant – Morgan Stanley

Patrick Donnelly – Citi

Matthew Sykes – Goldman Sachs

Kyle Mikson – Canaccord

Julia Qin – J.P. Morgan

Mason Carrico – Stephens

Michael Ryskin – Bank of America

Operator

Hello, everyone, and welcome to the 10x Genomics’ First Quarter 2023 Earnings Conference Call. My name is Bruno, and I will be the operator of today. [Operator Instructions]

I will now hand over to your host, Cassie Corneau. Cassie, please go ahead.

Cassie Corneau

Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the first quarter ended March 31, 2023. If you have not received this news release or if you would like to be added to the company’s distribution list, please send an e-mail to investors@10xgenomics.com. An archived webcast of this call will be available on the Investor tab of the company’s website 10xgenomics.com for at least 45 days following this call.

So we begin, I’d like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual risks or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties and factors that could cause results to differ appears in the press release 10x Genomics issued today, and in the documents and reports filed by 10x Genomics from time to time with the Securities and Exchange Commission. 10x Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise.

Joining the call today are Serge Saxonov, our CEO and Co-Founder; and Justin McAnear, our Chief Financial Officer. We will host a question-and-answer session after our prepared remarks. We ask analysts to please keep to one question and one follow up, so that we may accommodate everyone in the queue.

With that, I will now turn the call over to Serge.

Serge Saxonov

Thanks, Cassie, and good afternoon, everyone. On today’s call, I will start with an overview of our first quarter performance across our leading portfolio of single cell and spatial technologies. Next, I will discuss our progress, momentum and the exciting opportunities we have ahead in each of our three platforms. And I’ll share why based on early yet overwhelmingly positive feedback we hear from our customers, we firmly believe Xenium is the best system for in situ analysis. Then I’ll turn the call over to Justin for a more detailed look at our financials, business trends and outlook for the rest of the year.